Open Access

Rhinocerebral zygomycosis with pansinusitis in a 14-year-old girl with type 1 diabetes: a case report and review of the literature

  • Annalisa di Coste1Email author,
  • Francesco Costantino1,
  • Luigi Tarani1,
  • Vincenzo Savastano1,
  • Claudio Di Biasi2,
  • Laura Schiavi1,
  • Ilaria Ernesti1,
  • Taulant Melengu1 and
  • Marzia Duse1
Italian Journal of Pediatrics201339:77

DOI: 10.1186/1824-7288-39-77

Received: 10 October 2013

Accepted: 7 December 2013

Published: 10 December 2013

Abstract

Background

Zygomycosis is a rare life-threatening fungal infection affecting mostly patients with predisposing conditions such as diabetes mellitus, immunodeficiency, haemochromatosis or major trauma.

Methods

We describe a case of rhinocerebral zygomycosis in a girl with type 1 diabetes and review previous published cases and treatment options.

Results

A 14-year-old girl with type 1 diabetes mellitus occurred with dental pain, facial swelling, ecchymosis and left eye decreased visual acuity, unresponsive to antibiotic therapy. The coltures of the sinusal mucosa were positive for fungal species belonging to the Zygomycetes. She performed antifungal therapy with posaconazole (POS) with a very slow improvement and a poor glycemic control, leading to blindness of the left eye.

Conclusion

Our report adds further awareness on rhinocerebral zygomycosis and emphasizes on urgent diagnosis and timely management of this potentially fatal fungal infection through an adequate treatment.

Keywords

Rhinocerebral zygomycosis Diabetes Maxillary sinus Endoscopic Sinus Surgery Posaconazole

Background

Zygomycosis is a rare life-threatening opportunistic fungal infection in humans, that often complicates diabetes mellitus and primary and acquired immunodeficiencies characterised by defects of the cell-mediated immunity. Other predisposing factors include steroid therapy, organ transplantation and cytotoxic chemotherapy [1]. The causative organism is an aerobic saprophytic fungus belonging to the order of Mucorales of the class Zygomycetes. It is ubiquitous insoil, grows rapidly and constantly discharges spores into the environment [2]. Infection is usually caused by inhalation of sporangiospores or via direct contamination of skin wounds, especially burns. The lungs, nasal cavity and paranasal sinuses, gut and cutaneous tissues are therefore the most common sites for primary infection. At onset, Rhinocerebral Zygomycosis presents with different clinical features such as blindness, cranial nerve palsies, eye proptosis and pain. Fungal hyphae preferentially invade the walls of blood vessels producing thrombi and infarction. The resulting progressive tissue ischaemia and necrosis of deep tissues may include muscle and fat, ultimately leading to multiorgan failure and sepsis. The central nervous system can be invaded by Zygomycetes either contiguously from adjacent paranasal sinuses (rhinocerebral zygomycosis), or haematogenously from a remote site of infection [3]. We report a case of necrotizing invasive rhinocerebral zygomycosis in a 14-year-old girl with type 1 diabetes and review previous reported cases from 1980 to 2012.

Materials and methods

Case presentation

A 14-year-old caucasian girl is followed at our Department of Pediatrics for type 1 diabetes mellitus since the age of three years with poor glycemic control despite regular insulin therapy. She occurred with a 7-day history of dental pain, facial swelling (extending superiorly from the supraorbital margin and inferiorly to the angle of the mouth), and ecchymosis in the left periorbital region with decreased visual acuity and colour vision, unresponsive to antibiotic therapy with amoxicillin. Physical examination showed left-sided facial numbness, lagophthalmos with inability to complete closure of the left eyelid and tongue deviation to the left. Intraorally there were carious lesions and low sensitivity of the upper teeth. Biochemical investigations revealed neutrophilia and increasing of inflammatory markers. The electromyography showed a severe VII nerve damage. Radiographic examination showed haziness of left maxillary sinus with erosion of lateral sinus wall. Magnetic resonance imaging of her head revealed a marked mucosal thickening of the left maxillary sinus extended to the sphenoid, ethmoid and frontal sinus with moderate inflammatory effusion (Figure 1). For three times inflammatory tissue was excised from the sinuses through an Endoscopic Sinus Surgery for microbial eradication and histopathologic examination. The tissue biopsy showed fragments of mucosa lined by respiratory epithelium with chronic aspecific inflammatory infiltrate and growed fungal species belonging to the Zygomycetes. After a 20-day treatment with imipenem, teicoplanin, metronidazole and aciclovir, she was given intravenous amphotericin B to which posaconazole (POS) was immediately replaced, due to the onset of side effects such as hyperglycemia, marked hypothermia and profuse sweating. The follow-up magnetic resonance images showed progression of the disease with significant intracranial extension. The magnetic resonance angiography showed the involvement of the neurovascular retromandibular axis and left cavernous sinus with occlusion of ipsilateral cavernous carotid and increased signal of the walls of the left middle cerebral artery caused by arteritis. She continued antifungal drug therapy and clinic follow-up showing a very slow improvement, a poor glycemic control and many recurrences, leading to blindness of the left eye.
Figure 1

Magnetic resonance imaging of head. A. Postgadolinium T1-weighted axial magnetic resonance image showing nonenhancing tissue (arrow) in the left nasal cavity and periorbital site compatible with necrotic mucosa. B. Similar technique showing note semiocclusion of the left internal carotid artery (arrow) and thrombosis of the right cavernous sinus, although there was no radiographic evidence of cerebral infarction.

Results

Zygomycosis is rare in pediatric patients, and there are few reports in the literature. We performed a MEDLINE search for articles published in the English-language literature, ages: 0–18 years, from January 1980 to September 2013. The search terms used were: rhinocerebral zygomycosis or mucormycosis and case report.

Our search yielded a total of 25 articles including 28 case reports (Table 1). Cases included were those with acute zygomycosis infection in the rhinocerebral region diagnosed by histology with or without a positive culture, with hematologic malignancies or type 1 diabetes as predisposing factors. Fifteen out of 28 cases (53.6%) of rhinocerebral zygomycosis from these case series were found in patients with type 1 diabetes, twelve (42.8%) in patients with hematologic malignancies and one (3.6%) in a patient with autoimmune hepatitis.
Table 1

Pediatric rhinocerebral zygomycosis: review of the literature from 1980 to 2013

Author

Cases (Number)

Sex

Ages (years)

Underlying condition

Treatment

Outcome

Kilpatrick et al. [4]. 1984

1

F

18

DM 1

Surgery, antifungal therapy

Survived with left orbital exenteration and ethmoidectomy.

Kemper et al. [5]. 1993

1

F

18

DM 1

Surgery, L-AmB, HOT

Survived with right eye exenteration

Garces et al. [6]. 1994

1

M

6

Hematologic malignancy

Surgery

Deceased

Moll et al. [7]. 1994

1

Unknown

12

DM 1

Surgery, antifungal therapy

Survived with minimal left cranial nerve palsies

Shah et al. [8]. 1997

1

M

15

DM 1

L-AmB and HOT

Survived with a ventriculoperitoneal shunt, right nonreactive pupil, minimal residual physical disability

Kameh et al. [9] 1997

1

M

13 months

DM 1

Surgery, L-AmB

Deceased

Adler et al. [10]. 1998

1

M

16

DM 1

Surgery, L-AmB

Survived

Lee et al. [11] 1998

1

M

10

DM 1

Surgery, L-AmB

Survived with open craniotomy for abscess resection

Khanna et al. [12]. 1998

1

F

11

DM 1

Surgery, L-AmB

Deceased

Parkin et al. [13]. 2000

2

M; M

13; 3

Hematologic malignancy

G-CSF, L-AmB

Deceased for other cause; survived after bone marrow transplant

Ryan et al. [14]. 2001

2

F; M

9;3

Hematologic malignancy

Surgery, L-AmB

Deceased

Gessesse et al. [15]. 2001

1

M

11

DM 1

Unknown

Deceased

Wehl et al. [16]. 2002

1

M

9 months

Hematologic malignancy

L-AmB

Deceased

Hamilton et al. [17]. 2003

1

M

14

DM 1

Surgery, antibiotics, HOT

Survived with enucleation of right eye

Simmons et al. [18]. 2005

1

F

8

DM 1

Surgery, L-AmB, HOT, Interferon-G, POS, GM-CSF

Survived

Sorensen et al. [19]. 2006

1

F

10

Hematologic malignancy

L-AmB, POS, Caspofungin, surgery

Deceased for other cause

Popa et al. [20] 2008

1

F

7

Hematologic malignancy

L-AmB

Survived after neurosurgical debridement of the left temporal abscess

Garner et al. [21]. 2008

2

M; M

5; 15

Hematologic malignancy

L-AmB, POS

Survived

Ganesh et al. [22] 2008

1

M

14

DM 1

L-AmB, itraconazole

Survived

Tarani et al. [23]. 2009

1

F

12

DM 1

L-AmB, GM-CSF, HOT, surgery, POS

Survived

Ibrahim et al. [24]. 2009

1

F

12

DM 1

L-AmB, POS

Survived

Skiada et al. [3]. 2009

1

M

2

Hematologic malignancy

L-Am B, POS

Vegetative state

Safder et al. [25]. 2010

1

F

12

Autoimmune hepatitis

Surgery, L-AmB

Survived with right eye exenteration

Nirmala et al. [26]. 2011

1

M

12

DM 1

L-AmB

Survived

Prasad et al. [27]. 2012

1

F

15

Hematologic malignancy

Surgery and L-AmB

Deceased

Abbreviations: M Male, F Female, DM 1 Type 1 Diabetes, L-Amb Liposomal Amphotericin B, HOT Hyperbaric Oxygen Therapy, POS Posaconazole, GM-CFS Granulocyte Macrophage Colony Stimulating Factor.

In described pediatric cases rhinocerebral zygomycosis presents with a characteristic onset: cranial nerve palsies (66.7% of cases), facial/eye swelling or blindness (40%), eye proptosis (33.3%), periorbital cellulitis or pain (20%), epistaxis, headaches, nasal discharge, decreasing consciousness, dysarthria and otalgia (6.7%).

All cases have the involvement of at least one eye. All patients underwent surgery and/or therapy with amphotericin B and other antifungal agents. The 25% of patients with type 1 diabetes has passed the infection uncomplicated, while the 40% underwent to complications such as eye exenteration, partial loss of vision, invasive surgery and nerve palsies. The overall mortality was 20% in cases with type 1 diabetes and 50% in cases with other predisposing factors. The mortality rate was significantly higher when the central nervous system was involved compared to sinus or sino-orbital involvement only.

Discussion

The Zigomycosis’ predisposing factors are uncontrolled diabetes, lymphomas, leukemias, renal failure, organ transplant, long-term corticosteroid and immunosuppressive therapy [28]. Hyperglycemia, usually with an associated metabolic acidosis, is responsible for impaired neutrophil function, neuropathies and vascular insufficiency leading to a diminished resistance to infections and altered tissue response. In ketoacidosis, the acid environment due to the increase in glucose levels and the increase in levels of free iron ions favour fungal growth [2].

The clinical onset of the Rhinocerebral Zygomycosis in our report and in most cases is characterized by cranial nerve palsies, facial/eye swelling and blindness, less frequently by decreasing consciousness.

Mucormycosis is known for having a very poor prognosis: survival rates are currently thought to exceed 80%. Even with successful treatment, Mucorales can reappear during future courses of chemotherapy and neutropenia [29]. There may be predictive factors on the evolution of complications: patients who presented with “blindness” seem to have a higher prevalence of survival (p ≤ 0.04) while patients who presented with “decreased consciousness” seem to have an higher prevalence of death (p ≤ 0.04). With the advent of potent antifungal medications, a combination of surgery, medication and correction of the underlying conditions has provided better outcomes [26]. Surgery needs to be radical with an aim to remove all devitalized tissue, and has to be repeated based on disease progression. The new triazole POS has a broad antifungal spectrum against filamentous fungi. The use of POS seems to be associated with a high prevalence of survival with or without outcome (p ≤ 0.04). This is important as standard therapy with amphotericin B often fails [23].

Conclusion

The zygomycosis may present with specific clinical symptoms in patients with predisposing conditions. “Blindness” seems to be correlated with survival predictive factors while “decreased consciousness” seems to be associated with severe outcome.

Early diagnosis of zygomycosis and meticulous broad spectrum antifungal therapy are necessary to avoid the further spread of infection, which may lead to high morbidity and mortality. The timely use of POS alone or in combination with other therapies seems to be associated with a high prevalence of survival with or without outcome.

Larger studies and populations are needed to test if these relationships are casual or real. It is important to understand and implement the treatment options which can help to manage these patients with peculiar onset before the coltures results. Knowledge of potentially devastating complications can help to prevent the unfortunate consequences.

Written informed consent was obtained from the patient’s parents for publication of this Case report and any accompanying images. A copy of the written consent is available for review by the Editor-in-Chief of this journal.

Declarations

Authors’ Affiliations

(1)
Department of Pediatrics, Policlinico Umberto I, “Sapienza” University of Rome
(2)
Department of Radiology, Policlinico Umberto I, “Sapienza” University of Rome

References

  1. Buhl MR, Joseph TP, Snelling BE, Buhl L: Temporofacial Zygomycosis in a pregnant woman. Infection. 1992, 20: 230-232. 10.1007/BF02033066.View ArticlePubMedGoogle Scholar
  2. Ribeiro NFF, Cousin GCS, Wilson GE, Butterworth DM, Woodwards RTM: Lethal invasive mucormycosis: case report and recommendations for treatment. Int J Oral Maxillofac Surg. 2001, 30: 156-159. 10.1054/ijom.2000.0010.View ArticlePubMedGoogle Scholar
  3. Skiada A, Vrana L, Polychronopoulou H, Prodromou P, Chantzis A, Tofas P, Daikos GL: Disseminated zygomycosis with involvement of the central nervous system. Clin Microbiol Infect. 2009, 15 (Suppl. 5): 46-49.View ArticlePubMedGoogle Scholar
  4. Kilpatrick C, Tress B, King J: Computed tomography of rhinocerebral mucormycosis. Neuroradiology. 1984, 26: 71-73. 10.1007/BF00328210.View ArticlePubMedGoogle Scholar
  5. Kemper J, Kuijper EJ, Mirck PG, Balm AJ: Recovery from rhinocerebral mucormycosis in a ketoacidotic diabetic patient: a case report. J Laryngol Otol. 1993, 107: 233-235. 10.1017/S0022215100122716.View ArticlePubMedGoogle Scholar
  6. Garces P, Mueller D, Trevenen C: Rhinocerebral mucormycosis in a child with leukemia: CT and MRI findings. Pediatr Radiol. 1994, 24: 50-51. 10.1007/BF02017662.View ArticlePubMedGoogle Scholar
  7. Moll GW, Raila FA, Liu GC, Conerly AW: Rhinocerebral mucormycosis in IDDM: Sequential magnetic resonance imaging of long-term survival with intensive therapy. Diabetes Care. 1994, 17: 1348-1353. 10.2337/diacare.17.11.1348.View ArticlePubMedGoogle Scholar
  8. Shah PD, Peters KR, Reuman PD: Recovery from rhinocerebral mucormycosis with carotid artery occlusion: a pediatric case and review of the literature. Pediatr Infect Dis J. 1997, 16: 68-71. 10.1097/00006454-199701000-00015.View ArticlePubMedGoogle Scholar
  9. Kameh DS, Gonzalez OR: Fatal Rhino-orbital-cerebral zygomycosis. Southern Medical Journal. 1997, 90: 1133-1136. 10.1097/00007611-199711000-00015.View ArticlePubMedGoogle Scholar
  10. Adler DE, Milhorat TH, Miller JI: Treatment of rhinocerebral mucormycosis with intravenous interstitial, and cerebrospinal fluid administration of amphotericin B: case report. Neurosurgery. 1998, 42: 644-649. 10.1097/00006123-199803000-00037.View ArticlePubMedGoogle Scholar
  11. Lee EJ, Lee MY, Hung YC, Wang LC: Orbital rhinocerebral mucormycosis associated with diabetic ketoacidosis: report of survival of a 10-year-old boy. J Formos Med Assoc. 1998, 97: 720-723.PubMedGoogle Scholar
  12. Khanna SK, Soumekh B, Bradley JS, Billman G, Kearns DB, Spear RM, Peterson BM: A case of fatal rhinocerebral mucormycosis with new onset diabetic KETO-Acidosis. Journal of Diabetes and Its Complications. 1998, 12: 224-227. 10.1016/S1056-8727(97)00078-0.View ArticlePubMedGoogle Scholar
  13. Parkyn T, McNinch AW, Riordan T, Mott M: Zygomycosis in relapsed acute leukaemia. Journal of Infection. 2000, 41: 265-282. 10.1053/jinf.2000.0397.View ArticlePubMedGoogle Scholar
  14. Ryan M, Yeo S, Maguire A, Webb D, O’Marcaigh A, McDermott M, Butler K, O’Meara A: Rhinocerebral zygomycosis in childhood acute lymphoblastic leukaemia. Eur J Pediatr. 2001, 160: 235-238. 10.1007/s004310000703.View ArticlePubMedGoogle Scholar
  15. Gessesse M, Chali D, Wolde-Tensai B, Ergete W: Rhinocerebral mucormycosis in an 11-year-old boy. Ethiop Med J. 2001, 39: 341-348.PubMedGoogle Scholar
  16. Wehl G, Hoegler W, Kropshofer G, Meister B, Fink FM, Heitger A: Rhinocerebral mucormycosis in a boy with recurrent acute lymphoblastic leukemia: long-term survival with systemic antifungal treatment. Journal of Pediatric Hematology/Oncology. 2002, 24: 492-494. 10.1097/00043426-200208000-00017.View ArticlePubMedGoogle Scholar
  17. Hamilton JF, Bartkowski HB, Rock JP: Management of CNS mucormycosis in the pediatric patient. Pediatr Neurosurg. 2003, 38: 212-215. 10.1159/000069101.View ArticlePubMedGoogle Scholar
  18. Simmons JH, Zeitler PS, Fenton LZ, Abzug MJ, Fiallo-Scharer RV, Klingensmith GJ: Rhinocerebral mucormycosis complicated by internal carotid artery thrombosis in a pediatric patient with type 1 diabetes mellitus: a case report and review of the literature. Pediatric Diabetes. 2005, 6: 234-238. 10.1111/j.1399-543X.2005.00118.x.View ArticlePubMedGoogle Scholar
  19. Sorensen J, Becker M, Porto L: Rhinocerebral zygomycosis in a young girl undergoing allogeneic stem cell transplantation for severe aplastic anaemia. Mycoses. 2006, 49 (Suppl. 1): 31-36.View ArticlePubMedGoogle Scholar
  20. Popa G, Blag C, Sasca F: Rhinocerebral mucormycosis in a child with acute lymphoblastic leukemia a case report. J Pediatr Hematol Oncol. 2008, 30: 163-165. 10.1097/MPH.0b013e31815c255f.View ArticlePubMedGoogle Scholar
  21. Garner D, Machin K: Investigation and management of an outbreak of mucormycosis in a paediatric oncology unit. Journal of Hospital Infection. 2008, 70: 53-59. 10.1016/j.jhin.2008.05.017.View ArticlePubMedGoogle Scholar
  22. Ganesh R, Manikumar S, Vasanthi T: Rhinocerebral mucormycosis in an adolescent with type 1 diabetes mellitus: case report. Ann Trop Paediatr. 2008, 28: 297-300. 10.1179/146532808X375477.View ArticlePubMedGoogle Scholar
  23. Tarani L, Costantino F, Notheis G, Wintergerst U, Venditti M, Di Biasi C, Friederici D, Pasquino AM: Long-term posaconazole treatment and follow-up of rhino-orbital-cerebral mucormycosis in a diabetic girl. Pediatric Diabetes. 2009, 10: 289-293. 10.1111/j.1399-5448.2008.00465.x.View ArticlePubMedGoogle Scholar
  24. Ibrahim M, Chitnis S, Fallon K: Rhinocerebral mucormycosis in a 12-year-old girl. Arch Neurol. 2009, 66: 272-273.View ArticlePubMedGoogle Scholar
  25. Safder S, Carpenter JS, Roberts TD, Bailey N: The “Black Turbinate” sign: an early MR imaging finding of nasal Mucormycosis. Am J Neuroradiol. 2010, 31: 771-774. 10.3174/ajnr.A1808.View ArticlePubMedGoogle Scholar
  26. Nirmala SV, Lalitha V, Sivakumar N, Kiran Kumar K, Srikanth M: Mucormycosis associated with juvenile diabetes. J Indian Soc Pedod Prev Dent. 2011, 29 (Suppl 2): 87-91.View ArticleGoogle Scholar
  27. Prasad K, Lalitha RM, Reddy EK, Ranganath K, Srinivas DR, Singh J: Role of early diagnosis and multimodal treatment in rhinocerebral mucormycosis: experience of 4 cases. J Oral Maxillofac Surg. 2012, 70: 354-362. 10.1016/j.joms.2011.02.017.View ArticlePubMedGoogle Scholar
  28. Tryfon S, Stanopoulos I, Kakavelas E, Nikolaidou A, Kioumis I: Rhinocerebral Mucormycosis in a patient with latent diabetes mellitus: a case report. J Oral Maxillofac Surg. 2002, 60: 328-330. 10.1053/joms.2002.30600.View ArticlePubMedGoogle Scholar
  29. Aras MH, Kara MI, Erkiliç S, Ay S: Mandibular Mucormycosis in Immunocompromised patients: report of 2 cases and review of the literature. J Oral Maxillofac Surg. 2012, 70: 1362-1368. 10.1016/j.joms.2011.05.012.View ArticlePubMedGoogle Scholar

Copyright

© di Coste et al.; licensee BioMed Central Ltd. 2013

This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.

Advertisement